A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT06944496 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06944496
Sponsor: RemeGen Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric Carcinoma

Start date: 2025-05-15
Primary completion: 2028-05-15
Enrollment: 616

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.